LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
Healthcare
$40.06 -1.30%
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
52W Low $13.36High $33.47
Volume 0.36M
Average 0.23M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$35.21M
FY 2025 · Annual
Investing Cash Flow
-$39.89M
FY 2025 · Annual
Financing Cash Flow
$302.56M
FY 2025 · Annual
+689.7% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (14.35M) | (6.28M) | (63.1M) | (25.21M) |
| Depreciation & Amortization | 2K | 4K | 91K | 321K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 431K | 295K | 3.16M | 0 |
| Change in Working Capital | 86K | (1.31M) | 3.31M | (13.65M) |
| Accounts Receivables | 0 | (154K) | 114K | (268K) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | (910K) |
| Other Working Capital | 86K | (1.16M) | 3.2M | (12.47M) |
| Other Non-Cash Items | 11.1M | (4.81M) | 3.49M | 3.33M |
| Operating Cash Flow | (2.73M) | (12.09M) | (53.05M) | (35.21M) |
| Capital Expenditures | 0 | (25K) | (769K) | (52K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (33.99M) | (29.75M) | (44.84M) |
| Sales of Investments | 123K | 6M | 53.75M | 5M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 123K | (28.01M) | 23.23M | (39.89M) |
| Debt Repayment | 25.01M | 725K | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 302.56M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.95M) | (2.05M) | (1.69M) | 0 |
| Financing Cash Flow | 22.96M | 33.68M | 38.32M | 302.56M |
| Effect of Forex Changes | 0 | 0 | 0 | (272K) |
| Net Change in Cash | 20.36M | (6.43M) | 8.5M | 227.2M |
| Free Cash Flow | (2.73M) | (12.12M) | (53.82M) | (35.26M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$25.2M
+ D&A$321.0K
+ Stock-Based Comp$0
+ Deferred Tax$0
- Working Capital-$13.7M
+ Other Non-Cash$3.3M
= Operating Cash Flow-$35.2M
- Capex-$52.0K
= Free Cash Flow-$35.3M
Analysis
FY2025 free cash flow is -$35.3M. FCF conversion is 139.9% of net income. Operating cash flow was -$35.2M, with capex of -$52.0K. The largest bridge item is Working Capital at -$13.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 13, 2026 |
Does LBRX generate free cash flow?
LB Pharmaceuticals Inc Common Stock (LBRX) generated -$35.26M of free cash flow in fiscal 2025.
How much operating cash flow does LBRX produce?
Operating cash flow was -$35.21M, before capital expenditures of $52,000.00.
Continue the stock analysis
Jump to another research area for this company.